bioMérieux : CA T1 2024 en ligne avec les attentes du CSS – Guidance maintenues. – CMD et annonce d’un Plan à 5 ans (solide croissance /amélioration des marges)
>CA T1 2024 : +10% lfl - Le CA T1 ressort à 965 M€ (+6,6% et +9,8% lfl). Les Applications Cliniques sont en hausse de 7,7% (+10,7% à ptc) et les Applications Industrielles progressent de 0,8% (+5,3% à ptc).Pour 2024, le management reconduit sa guidance (croissance de 6 à 8% pour un c.EBIT en hausse de 10% lfl. (670 M€) avec toutefois un effet FX de -50 M€, soit plutôt 621 M€ en milieu de fourchette du CAe). Le CSS attend 3903 M€, +7,6% org. (CA : 3903 M€e - cEBIT...Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.